Home LiteratureArticle Details
PMID: 9914879 Published · ppublish English Journal Article Review

Developing recombinant and synthetic vaccines for the treatment of melanoma.

Current opinion in oncology ·Vol. 11 ·No. 1 ·1999-01-00 ·Pages 50-7

Restifo NP, Rosenberg SA

Abstract

To develop new vaccines for the treatment of patients with cancer, target antigens presented on tumor cell surfaces have been cloned. Many of these antigens are non-mutated differentiation antigens and are expressed by virtually all melanomas, making them attractive components for a widely efficacious melanoma vaccine. These antigens are also expressed by melanocytes, however, and are likely to be subject to immune tolerance. A central challenge for tumor immunologists has thus been the breaking of tolerance to cancer antigens. We review recent clinical trials using experimental cancer vaccines, including recent evidence that therapeutic vaccines can induce objective responses in patients with metastatic malignant melanoma. We focus on the foundations of these approaches in new experimental animal models designed to test novel vaccines and report on what these new models predict for the future development of therapeutic vaccines for cancer.

MeSH Terms
Adjuvants, Immunologic/therapeutic use Adoptive Transfer Antigens, Neoplasm/genetics Cancer Vaccines/therapeutic use Clinical Trials as Topic Disease Models, Animal Humans Melanoma/therapy Tumor Escape/physiology Vaccines, Synthetic/therapeutic use
Chemicals
Adjuvants, Immunologic Antigens, Neoplasm Cancer Vaccines Vaccines, Synthetic
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Restifo N P
National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1502, USA.
Rosenberg S A
References (82)
82 references, click to expand
  1. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
    J Immunol. 1999 Aug 1;163(3):1690-5 PMID: 10415076
  2. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.
    Science. 1994 Apr 29;264(5159):716-9 PMID: 7513441
  3. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
    J Exp Med. 1994 Jul 1;180(1):347-52 PMID: 7516411
  4. Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
    Cancer Res. 1994 Aug 1;54(15):4155-61 PMID: 7518351
  5. Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
    Cancer Res. 1995 Apr 15;55(8):1741-7 PMID: 7536130
  6. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
    J Immunol. 1995 Aug 1;155(3):1343-8 PMID: 7543520
  7. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    N Engl J Med. 1995 Oct 19;333(16):1038-44 PMID: 7675046
  8. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression.
    J Immunol. 1995 Apr 15;154(8):3961-8 PMID: 7706734
  9. Antigen processing in vivo and the elicitation of primary CTL responses.
    J Immunol. 1995 May 1;154(9):4414-22 PMID: 7722298
  10. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
    J Immunol. 1995 May 1;154(9):4651-7 PMID: 7722317
  11. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
    J Immunol. 1995 May 1;154(9):4685-92 PMID: 7722321
  12. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
    J Immunol. 1995 May 15;154(10):5282-92 PMID: 7730632
  13. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
    J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66 PMID: 8028037
  14. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes.
    Eur J Immunol. 1994 Mar;24(3):759-64 PMID: 8125142
  15. Identification of human cancers deficient in antigen processing.
    J Exp Med. 1993 Feb 1;177(2):265-72 PMID: 8426105
  16. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
    J Natl Cancer Inst. 1996 Jan 17;88(2):100-8 PMID: 8537970
  17. A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes.
    Eur J Immunol. 1996 Jan;26(1):224-30 PMID: 8566071
  18. Enhancement of antitumor immunity by CTLA-4 blockade.
    Science. 1996 Mar 22;271(5256):1734-6 PMID: 8596936
  19. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
    J Immunol. 1996 Jan 1;156(1):224-31 PMID: 8598466
  20. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
    J Immunol. 1996 Jan 1;156(1):238-45 PMID: 8598468
  21. IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
    J Immunol. 1996 May 1;156(9):3357-65 PMID: 8617961
  22. Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen.
    J Exp Med. 1996 Mar 1;183(3):1131-40 PMID: 8642255
  23. Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
    J Exp Med. 1996 May 1;183(5):1965-71 PMID: 8642306
  24. Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
    Cancer Res. 1996 Jun 15;56(12):2832-6 PMID: 8665522
  25. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.
    J Immunol. 1996 Sep 15;157(6):2539-48 PMID: 8805655
  26. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4 PMID: 8859727
  27. The new vaccines: building viruses that elicit antitumor immunity.
    Curr Opin Immunol. 1996 Oct;8(5):658-63 PMID: 8902391
  28. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Science. 1996 Nov 22;274(5291):1363-6 PMID: 8910274
  29. Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100.
    J Immunol. 1996 Dec 1;157(11):5027-33 PMID: 8943411
  30. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes.
    J Exp Med. 1996 Dec 1;184(6):2207-16 PMID: 8976176
  31. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
    J Immunol. 1997 Feb 15;158(4):1796-802 PMID: 9029118
  32. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.
    Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 PMID: 9050879
  33. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
    J Exp Med. 1997 Feb 3;185(3):453-9 PMID: 9053445
  34. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease.
    Blood. 1997 Mar 15;89(6):1978-86 PMID: 9058719
  35. Route of immunization and the therapeutic impact of recombinant anticancer vaccines.
    J Natl Cancer Inst. 1997 Mar 5;89(5):390-2 PMID: 9060962
  36. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.
    Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3183-8 PMID: 9096367
  37. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
    J Immunother. 1997 Jan;20(1):15-25 PMID: 9101410
  38. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine.
    J Immunother. 1997 Jan;20(1):48-59 PMID: 9101413
  39. Cancer vaccines based on the identification of genes encoding cancer regression antigens.
    Immunol Today. 1997 Apr;18(4):175-82 PMID: 9136454
  40. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
    Vaccine. 1997 Mar;15(4):387-94 PMID: 9141209
  41. The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.
    J Immunol. 1997 Jul 1;159(1):303-8 PMID: 9200467
  42. FLT3 ligand induces the generation of functionally active dendritic cells in mice.
    Cell Immunol. 1997 Aug 1;179(2):174-84 PMID: 9268501
  43. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma.
    J Exp Med. 1997 Aug 29;186(5):785-93 PMID: 9271594
  44. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.
    Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):12059-64 PMID: 9342362
  45. Genes coding for melanoma antigens recognised by cytolytic T lymphocytes.
    Eye (Lond). 1997;11 ( Pt 2):243-8 PMID: 9349420
  46. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice.
    Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12557-61 PMID: 9356488
  47. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.
    J Natl Cancer Inst. 1997 Nov 5;89(21):1595-601 PMID: 9362157
  48. Prospects for adoptive T cell therapy.
    Curr Opin Immunol. 1997 Oct;9(5):702-8 PMID: 9368780
  49. Natural killer cell lines kill autologous beta2-microglobulin-deficient melanoma cells: implications for cancer immunotherapy.
    Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13140-5 PMID: 9371813
  50. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
    J Exp Med. 1998 Jan 19;187(2):265-70 PMID: 9432985
  51. Cancer Tumor antigens.
    Curr Opin Immunol. 1997 Oct 1;9(5):681-3 PMID: 9438857
  52. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 PMID: 9448305
  53. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
    Int J Cancer. 1998 Jan 30;75(3):451-8 PMID: 9455808
  54. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
    J Immunother. 1998 Jan;21(1):27-31 PMID: 9456433
  55. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma.
    Cancer Res. 1998 Feb 1;58(3):380-3 PMID: 9458075
  56. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.
    Int J Cancer. 1998 Feb 9;75(4):517-24 PMID: 9466650
  57. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
    J Immunol. 1998 Mar 1;160(5):2099-106 PMID: 9498746
  58. Melanoma vaccines: prim and proper presentation.
    Nat Med. 1998 Mar;4(3):269-70 PMID: 9500593
  59. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
    Nat Med. 1998 Mar;4(3):321-7 PMID: 9500606
  60. Generation of stable CD4+ and CD8+ T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations.
    Cell Immunol. 1997 Dec 15;182(2):137-51 PMID: 9514698
  61. Homeostasis and self-tolerance in the immune system: turning lymphocytes off.
    Science. 1998 Apr 10;280(5361):243-8 PMID: 9535647
  62. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
    J Exp Med. 1998 Apr 20;187(8):1349-54 PMID: 9547346
  63. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33.
    J Immunol. 1998 Jan 15;160(2):890-7 PMID: 9551926
  64. CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.
    J Exp Med. 1998 May 18;187(10):1555-64 PMID: 9584134
  65. Cancer vaccines.
    Nat Med. 1998 May;4(5 Suppl):525-31 PMID: 9585204
  66. Genetic modification of T-cell clones for therapy of human viral and malignant diseases.
    Cancer J Sci Am. 1998 May;4 Suppl 1:S100-5 PMID: 9619278
  67. LAGE-1, a new gene with tumor specificity.
    Int J Cancer. 1998 Jun 10;76(6):903-8 PMID: 9626360
  68. An antigen recognized by autologous CTLs on a human bladder carcinoma.
    J Immunol. 1998 Jun 15;160(12):6188-94 PMID: 9637538
  69. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
    J Exp Med. 1998 Jul 20;188(2):277-86 PMID: 9670040
  70. The use of melanosomal proteins in the immunotherapy of melanoma.
    J Immunother. 1998 Jul;21(4):237-46 PMID: 9672845
  71. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
    J Immunol Methods. 1998 May 1;214(1-2):51-62 PMID: 9692858
  72. Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens.
    Cancer Res. 1998 Aug 15;58(16):3519-25 PMID: 9721852
  73. Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.
    Virology. 1998 Sep 15;249(1):89-97 PMID: 9740780
  74. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.
    Hum Gene Ther. 1998 Sep 1;9(13):1951-71 PMID: 9741433
  75. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.
    J Exp Med. 1998 Sep 21;188(6):1075-82 PMID: 9743526
  76. Cancer vaccines '98: a reductionistic approach. Bethesda, MD, USA, 27-28 April 1998.
    Mol Med Today. 1998 Aug;4(8):327 PMID: 9755448
  77. T cell-tumor cell: a fatal interaction?
    Cancer Immunol Immunother. 1998 Oct;47(2):65-71 PMID: 9769114
  78. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.
    J Immunol. 1998 Nov 1;161(9):4563-71 PMID: 9794383
  79. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.
    J Natl Cancer Inst. 1998 Dec 16;90(24):1881-7 PMID: 9862625
  80. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
    J Natl Cancer Inst. 1998 Dec 16;90(24):1894-900 PMID: 9862627
  81. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles.
    J Immunol. 1998 Dec 15;161(12):6985-92 PMID: 9862734
  82. Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
    Cancer Res. 1999 Jan 1;59(1):59-62 PMID: 9892185
Article Info
Journal
Current opinion in oncology
Abbr.
Curr Opin Oncol
ISSN
1040-8746
DOI
10.1097/00001622-199901000-00012
Published
1999-01-00
Pages
50-7
Language
English
Region
United States
NLM ID
9007265
PMCID
PMC1950783
Subset
IM
Grants
Intramural NIH HHS · Z01 BC010763-01 · United States
Intramural NIH HHS · Z99 CA999999 · United States
External Links
PubMed source DOI: 10.1097/00001622-199901000-00012 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2